IL128780A0 - An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase - Google Patents

An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase

Info

Publication number
IL128780A0
IL128780A0 IL12878097A IL12878097A IL128780A0 IL 128780 A0 IL128780 A0 IL 128780A0 IL 12878097 A IL12878097 A IL 12878097A IL 12878097 A IL12878097 A IL 12878097A IL 128780 A0 IL128780 A0 IL 128780A0
Authority
IL
Israel
Prior art keywords
polymerase
production
associated viruses
recombinant adeno
viruses utilizing
Prior art date
Application number
IL12878097A
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of IL128780A0 publication Critical patent/IL128780A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
IL12878097A 1996-09-06 1997-09-04 An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase IL128780A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2469996P 1996-09-06 1996-09-06
PCT/US1997/015716 WO1998010088A1 (en) 1996-09-06 1997-09-04 An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase

Publications (1)

Publication Number Publication Date
IL128780A0 true IL128780A0 (en) 2000-01-31

Family

ID=21821933

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12878097A IL128780A0 (en) 1996-09-06 1997-09-04 An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase

Country Status (6)

Country Link
EP (1) EP0931158A1 (en)
JP (1) JP2001500015A (en)
AU (1) AU722624B2 (en)
CA (1) CA2264482A1 (en)
IL (1) IL128780A0 (en)
WO (1) WO1998010088A1 (en)

Families Citing this family (216)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6924128B2 (en) 1994-12-06 2005-08-02 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant AAV vectors
US6995006B2 (en) 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6953690B1 (en) 1998-03-20 2005-10-11 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
AU5819599A (en) * 1998-09-11 2000-04-03 Regents Of The University Of California, The Recombinant adenovirus for tissue specific expression in heart
US6759237B1 (en) 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
JP4693244B2 (en) 1999-03-18 2011-06-01 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Compositions and methods for helperless production of recombinant adeno-associated virus
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
US6893865B1 (en) 1999-04-28 2005-05-17 Targeted Genetics Corporation Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles
US6793926B1 (en) 1999-05-27 2004-09-21 Genovo, Inc. Methods for production of a recombinant adeno-associated virus
US7115391B1 (en) 1999-10-01 2006-10-03 Genovo, Inc. Production of recombinant AAV using adenovirus comprising AAV rep/cap genes
NZ532635A (en) 2001-11-13 2007-05-31 Univ Pennsylvania A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method
SG2013034475A (en) 2001-11-21 2016-10-28 Univ Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
EP1944043A1 (en) 2001-11-21 2008-07-16 The Trustees of the University of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
JP4769417B2 (en) 2001-12-17 2011-09-07 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Adeno-associated virus (AAV) serotype 9 sequences, vectors containing the same and uses thereof
PT1453547T (en) 2001-12-17 2016-12-28 Univ Pennsylvania Adeno-associated virus (aav) serotype 8 sequences, vectors containing same, and uses therefor
JP2005532789A (en) 2002-03-15 2005-11-04 ワイス・ホールデイングス・コーポレーシヨン P4 protein variant of non-typeable Haemophilus influenzae with reduced enzymatic activity
ES2359473T3 (en) 2003-07-21 2011-05-23 Transgene S.A. MULTIFUNCTIONAL CYTOKINS.
WO2005030292A2 (en) 2003-09-26 2005-04-07 The Trustees Of The University Of Pennsylvania Methods, compositions and apparatus for delivering heterologous molecules to cells
ES2648241T3 (en) 2003-09-30 2017-12-29 The Trustees Of The University Of Pennsylvania Adeno-associated virus clades (AAV), sequences, vectors containing the same, and uses thereof
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
US20090054823A1 (en) 2004-09-30 2009-02-26 The Trustees Of The University Of Pennsylvania Perfusion circuit and use therein in targeted delivery of macromolecules
US7517870B2 (en) 2004-12-03 2009-04-14 Fondazione Telethon Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
ES2525067T3 (en) 2005-04-07 2014-12-17 The Trustees Of The University Of Pennsylvania Method of increasing the function of an AAV vector
MX2009000813A (en) 2006-07-27 2009-02-03 Wyeth Corp High-cell density fed-batch fermentation process for producing recombinant protein.
MX347246B (en) 2007-11-28 2017-04-19 Univ Pennsylvania Simian subfamily e adenoviruses sadv-39, -25.2, -26, -30, -37, and -38 and uses thereof.
WO2009105084A2 (en) 2007-11-28 2009-08-27 The Trustees Of The University Of Pennsylvania Simian subfamily c adenoviruses sadv-40, -31, and-34 and uses thereof
US8470310B2 (en) 2008-03-04 2013-06-25 The Trustees Of The University Of Pennsylvania Simian adenoviruses SAdV-36, -42.1, -42.2, and -44 and uses thereof
US8940290B2 (en) 2008-10-31 2015-01-27 The Trustees Of The University Of Pennsylvania Simian adenoviruses SAdV-43, -45, -46, -47, -48, -49, and -50 and uses thereof
PL2425000T3 (en) 2009-04-30 2019-08-30 The Trustees Of The University Of Pennsylvania Compositions for targeting conducting airway cells comprising adeno-associated virus constructs
CN102575232B (en) 2009-05-29 2015-07-22 宾夕法尼亚大学托管会 Simian adenovirus 41 and uses thereof
US20120309011A1 (en) * 2009-11-02 2012-12-06 Salk Institute For Biological Studies Targeting of modifying enzymes for protein evolution
DK2826860T3 (en) 2010-04-23 2018-12-03 Univ Massachusetts CNS targeting AAV vectors and methods for their use
AU2011305249B2 (en) 2010-09-26 2015-07-23 Da Yu Enterprises, L.L.C. Method of recombinant macromolecular production
AU2011332025B2 (en) 2010-11-23 2015-06-25 The Trustees Of The University Of Pennsylvania Subfamily E simian adenoviruses A1321, A1325, A1295, A1309 and A1322 and uses thereof
EP3202897B1 (en) 2010-12-09 2020-04-15 Institut Pasteur Diagnostic use of a fusion polypeptide comprising a viral protein and a mgmt enzyme
BR112013020734A2 (en) 2011-02-17 2017-06-13 Univ Pennsylvania compositions and methods for altering tissue specificity and enhancing aav9-mediated gene transfer
EP2710130B1 (en) 2011-05-19 2022-06-29 Fundación Pública Andaluza Progreso Y Salud Highly inducible dual-promoter lentiviral tet-on system
ES2716723T3 (en) 2011-09-20 2019-06-14 Univ North Carolina Chapel Hill Regulation of sodium channels by PLUNC proteins
US10640785B2 (en) 2011-11-22 2020-05-05 The Children's Hospital Of Philadelphia Virus vectors for highly efficient transgene delivery
US9638692B2 (en) 2011-12-09 2017-05-02 Institut Pasteur Multiplex immuno screening assay
PT2839014T (en) 2012-04-18 2021-03-19 Childrens Hospital Philadelphia Composition and methods for highly efficient gene transfer using aav capsid variants
KR20150014505A (en) 2012-05-18 2015-02-06 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof
EP2912069B1 (en) 2012-10-23 2019-07-31 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
WO2014068072A1 (en) 2012-10-31 2014-05-08 Institut Gustave-Roussy Identification, assessment and therapy of essential thrombocythemia with resistance to jak2 inhibitors
WO2014071182A1 (en) 2012-11-01 2014-05-08 Massachusetts Institute Of Technology Directed evolution of synthetic gene cluster
EP2917341B1 (en) 2012-11-08 2017-09-27 Centre National de la Recherche Scientifique (CNRS) New phosphodeoxyribosyltransferase mutant enzymes and uses thereof
JP6591956B2 (en) 2013-03-15 2019-10-16 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Compositions and methods for treating MPS1
EP3019620A4 (en) 2013-07-12 2017-01-18 The Children's Hospital of Philadelphia Aav vector and assay for anti-aav (adeno-associated virus) neutralizing antibodies
WO2015013313A2 (en) 2013-07-22 2015-01-29 The Children's Hospital Of Philadelphia Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
SI3116900T1 (en) 2014-03-09 2021-02-26 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of ornithine transcarbamylase (otc) deficiency
US10975391B2 (en) 2014-04-25 2021-04-13 University Of Massachusetts Recombinant AAV vectors useful for reducing immunity against transgene products
HUE054768T2 (en) 2014-05-02 2021-09-28 Genzyme Corp Aav vectors for retinal and cns gene therapy
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
PL3169341T3 (en) 2014-07-16 2019-12-31 Transgene Sa Oncolytic virus for expression of immune checkpoint modulators
JP6842410B2 (en) 2014-10-03 2021-03-17 ユニバーシティ オブ マサチューセッツ AAV vector identified by a novel high efficiency library
CN107073051B (en) 2014-10-21 2021-08-24 马萨诸塞大学 Recombinant AAV variants and uses thereof
MX2017005834A (en) 2014-11-05 2017-11-17 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease.
AU2015346162B2 (en) 2014-11-14 2022-02-10 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
CN112375760A (en) 2014-11-14 2021-02-19 沃雅戈治疗公司 Regulatory polynucleotides
WO2016094783A1 (en) 2014-12-12 2016-06-16 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
CN107427666B (en) 2015-01-30 2022-11-04 加利福尼亚大学校董 Subpial gene delivery system for spinal cord
AU2016219396B2 (en) 2015-02-10 2022-03-17 Genzyme Corporation Variant RNAi
SG10201907399RA (en) 2015-02-10 2019-09-27 Genzyme Corp Enhanced delivery of viral particles to the striatum and cortex
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
CA2978917A1 (en) 2015-03-10 2016-09-15 The Trustees Of Columbia University In The City Of New York Recombinant glut1 adeno-associated viral vector constructs and related methods for restoring glut1 expression
TWI707951B (en) 2015-04-08 2020-10-21 美商健臻公司 Production of oversized adeno-associated vectors
CA3019315A1 (en) 2015-04-23 2016-10-27 University Of Massachusetts Modulation of aav vector transgene expression
US11896651B2 (en) 2015-05-16 2024-02-13 Genzyme Corporation Gene editing of deep intronic mutations
KR102415896B1 (en) 2015-06-23 2022-06-30 더 칠드런스 호스피탈 오브 필라델피아 Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
CN115418357A (en) 2015-07-13 2022-12-02 皮沃特生物公司 Methods and compositions for improving plant traits
AU2016336328A1 (en) 2015-10-05 2018-04-19 Massachusetts Institute Of Technology Nitrogen fixation using refactored nif clusters
DK3364997T3 (en) 2015-10-22 2024-04-22 Univ Massachusetts ASPARTOACYLASE GENE THERAPY FOR THE TREATMENT OF CANAVAN'S DISEASE
US20180230489A1 (en) 2015-10-28 2018-08-16 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
US10385320B2 (en) 2015-12-02 2019-08-20 The Board Of Trustees Of The Leland Stanford Junior University Recombinant adeno-associated virus capsids with enhanced human skeletal muscle tropism
CA3012195A1 (en) 2016-02-03 2017-08-10 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type i
CA3012344A1 (en) 2016-02-12 2017-08-17 University Of Massachusetts Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
EP3417055B1 (en) 2016-02-16 2021-10-13 The Board of Trustees of the Leland Stanford Junior University Novel recombinant adeno-associated virus capsids resistant to pre-existing human neutralizing antibodies
AU2017222450A1 (en) 2016-02-22 2018-09-27 The University Of North Carolina At Chapel Hill Peptide inhibitors of calcium channels
RU2752882C2 (en) 2016-03-03 2021-08-11 Юниверсити Оф Массачусетс Closed-end linear duplex dna for non-viral gene transfer
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189959A1 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
GB201608046D0 (en) 2016-05-09 2016-06-22 Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The Treatment of complement-mediated disorders
RU2764587C2 (en) 2016-05-18 2022-01-18 Вояджер Терапьютикс, Инк. Methods and compositions for treatment of huntington's chorea
SG11201809699XA (en) 2016-05-18 2018-12-28 Voyager Therapeutics Inc Modulatory polynucleotides
CA3027784A1 (en) 2016-06-16 2017-12-21 Charite - Universitatsmedizin Berlin Neuropeptide-expressing vectors and methods for the treatment of epilepsy
MA45493A (en) 2016-06-27 2019-05-01 Aicuris Anti Infective Cures Gmbh HCMC ENTRY INHIBITORS.
KR20190096329A (en) 2016-07-05 2019-08-19 유니버시티 오브 매사추세츠 AAV2-mediated gene delivery of SFASL as a neuroprotective therapy in glaucoma
CA3030156A1 (en) 2016-07-07 2018-01-11 Iovance Biotherapeutics, Inc. Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
JP6994018B2 (en) 2016-07-26 2022-01-14 バイオマリン ファーマシューティカル インコーポレイテッド New adeno-associated virus capsid protein
TN2019000047A1 (en) 2016-08-15 2020-07-15 Genzyme Corp Methods for detecting aav
JP2019530737A (en) 2016-08-23 2019-10-24 アコーオス インコーポレイテッド Compositions and methods for treating non-aged hearing loss in human subjects
WO2018049261A1 (en) 2016-09-09 2018-03-15 Icellhealth Consulting Llc Oncolytic virus expressing immune checkpoint modulators
US10457940B2 (en) 2016-09-22 2019-10-29 University Of Massachusetts AAV treatment of Huntington's disease
EP3518966A1 (en) 2016-09-29 2019-08-07 GlaxoSmithKline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
TWI788307B (en) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
KR20190097240A (en) 2016-12-28 2019-08-20 트랜스진 에스.에이. Oncolytic viruses and therapeutic molecules
WO2018132774A1 (en) 2017-01-12 2018-07-19 Pivot Bio, Inc. Methods and compositions for improving plant traits
JP7307480B2 (en) 2017-04-05 2023-07-12 ユニバーシティ オブ マサチューセッツ mini gene therapy
EP3619299A1 (en) 2017-05-03 2020-03-11 BioMarin Pharmaceutical Inc. Improved lentiviruses for transduction of hematopoietic stem cells.
SG11201909868YA (en) 2017-05-05 2019-11-28 Voyager Therapeutics Inc Compositions and methods of treating huntington's disease
JP2020518258A (en) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Amyotrophic lateral sclerosis (ALS) treatment composition and method
RU2020100074A (en) 2017-06-13 2021-08-03 Флэгшип Пайониринг Инновейшнз V, Инк. COMPOSITIONS CONTAINING CURONS AND WAYS OF THEIR APPLICATION
JOP20190269A1 (en) 2017-06-15 2019-11-20 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
US11773407B2 (en) 2017-06-26 2023-10-03 Arizona Board Of Regents On Behalf Of Arizona State University CRISPR logic circuits for safer and controllable gene therapies
AU2018298133A1 (en) 2017-07-06 2020-01-23 The Trustees Of The University Of Pennsylvania AAV9-mediated gene therapy for treating mucopolysaccharidosis type I
CN111132626B (en) 2017-07-17 2024-01-30 沃雅戈治疗公司 Track array guidance system
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa Oncolytic viruses expressing agents targeting metabolic immune modulators
KR20200044793A (en) 2017-08-03 2020-04-29 보이저 테라퓨틱스, 인크. Compositions and methods for delivery of AAV
KR20200056428A (en) 2017-09-22 2020-05-22 젠자임 코포레이션 Variant RNAi
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
JP2021502060A (en) 2017-10-16 2021-01-28 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Treatment of amyotrophic lateral sclerosis (ALS)
BR112020012336A2 (en) 2017-12-19 2021-03-30 Akouos, Inc. ADMINISTRATION OF AAV MEDIATED THERAPEUTIC ANTIBODIES FOR INTERNAL EAR
EP3762500A1 (en) 2018-03-06 2021-01-13 Voyager Therapeutics, Inc. Insect cell manufactured partial self-complementary aav genomes
JP2021519065A (en) 2018-03-23 2021-08-10 ユニバーシティ オブ マサチューセッツ Gene therapy to treat bone disorders
US11608510B2 (en) 2018-03-30 2023-03-21 The Board Of Trustees Of The Leland Stanford Junior University Recombinant adeno-associated virus capsids with enhanced human pancreatic tropism
EP3784290A4 (en) 2018-04-27 2022-03-23 University of Massachusetts Aav capsids identified by in vivo library selection
AU2019257755A1 (en) 2018-04-27 2020-11-12 Voyager Therapeutics, Inc. Methods for measuring the potency of AADC viral vectors
EP3790394A4 (en) 2018-05-08 2022-07-27 Rutgers, the State University of New Jersey Aav-compatible laminin-linker polymerization proteins
SG11202010830WA (en) 2018-05-09 2020-11-27 Biomarin Pharm Inc Methods of treating phenylketonuria
TW202005978A (en) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 Novel liver targeting adeno-associated viral vectors
SG11202011296VA (en) 2018-05-15 2020-12-30 Voyager Therapeutics Inc Compositions and methods for the treatment of parkinson's disease
US20210230632A1 (en) 2018-05-15 2021-07-29 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
US20210214749A1 (en) 2018-05-16 2021-07-15 Voyager Therapeutics, Inc. Directed evolution
WO2019222441A1 (en) 2018-05-16 2019-11-21 Voyager Therapeutics, Inc. Aav serotypes for brain specific payload delivery
BR112020024285A2 (en) 2018-06-12 2021-03-02 Glaxosmithkline Biologicals S.A. adenovirus polynucleotides and polypeptides
EP3807404A1 (en) 2018-06-13 2021-04-21 Voyager Therapeutics, Inc. Engineered 5' untranslated regions (5' utr) for aav production
CN112567035A (en) 2018-07-02 2021-03-26 沃雅戈治疗公司 Treatment of amyotrophic lateral sclerosis and spinal cord related disorders
US20210355454A1 (en) 2018-07-24 2021-11-18 Voyager Therapeutics, Inc. Systems and methods for producing gene therapy formulations
EP3830265A1 (en) 2018-08-03 2021-06-09 Genzyme Corporation Variant rnai against alpha-synuclein
CN113166208A (en) 2018-10-02 2021-07-23 沃雅戈治疗公司 Redirecting tropism of AAV capsids
US20210348242A1 (en) 2018-10-04 2021-11-11 Voyager Therapeutics, Inc. Methods for measuring the titer and potency of viral vector particles
TW202028458A (en) 2018-10-05 2020-08-01 美商航海家醫療公司 Engineered nucleic acid constructs encoding aav production proteins
US20210371470A1 (en) 2018-10-12 2021-12-02 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
EP3867389A1 (en) 2018-10-15 2021-08-25 Voyager Therapeutics, Inc. Expression vectors for large-scale production of raav in the baculovirus/sf9 system
CN117969861A (en) 2018-10-25 2024-05-03 瑞泽恩制药公司 Method for analyzing viral capsid protein composition
WO2020097344A1 (en) 2018-11-08 2020-05-14 Arizona Board of Regents on Behalf Arizona State University Synthetic immunomodulation with a crispr super-repressor in vivo
WO2020112967A1 (en) 2018-11-29 2020-06-04 University Of Massachusetts Modulation of sptlc1 via recombinant adeno-associated vectors
US11166996B2 (en) 2018-12-12 2021-11-09 Flagship Pioneering Innovations V, Inc. Anellovirus compositions and methods of use
WO2020136232A1 (en) 2018-12-28 2020-07-02 Transgene Sa Immunosuppressive m2 protein
AU2020208467A1 (en) 2019-01-18 2021-08-05 Voyager Therapeutics, Inc. Methods and systems for producing AAV particles
US20220054655A1 (en) 2019-02-22 2022-02-24 University Of Massachusetts Oxr1 gene therapy
US20200299637A1 (en) 2019-03-19 2020-09-24 Massachusetts Institute Of Technology Control of nitrogen fixation in rhizobia that associate with cereals
TW202106879A (en) 2019-04-29 2021-02-16 美商航海家醫療公司 Systems and methods for producing baculoviral infected insect cells (biics) in bioreactors
WO2020227515A1 (en) 2019-05-07 2020-11-12 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
US20200362368A1 (en) 2019-05-14 2020-11-19 Biomarin Pharmaceutical Inc. Methods of redosing gene therapy vectors
EP4007814A1 (en) 2019-07-26 2022-06-08 Akouos, Inc. Methods of treating hearing loss using a secreted target protein
EP4010465A1 (en) 2019-08-09 2022-06-15 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
US20220364114A1 (en) 2019-08-26 2022-11-17 Voyager Therapeutics, Inc. Controlled expression of viral proteins
WO2021046155A1 (en) 2019-09-03 2021-03-11 Voyager Therapeutics, Inc. Vectorized editing of nucleic acids to correct overt mutations
CN114555814A (en) 2019-09-13 2022-05-27 罗特格斯新泽西州立大学 AAV-compatible laminin-linker polyproteins
JP2022549679A (en) 2019-09-27 2022-11-28 バイオマリン ファーマシューティカル インコーポレイテッド Characterization of Gene Therapy Viral Particles Using Size Exclusion Chromatography and Multi-Angle Light Scattering Techniques
KR20220133941A (en) 2020-01-29 2022-10-05 젠자임 코포레이션 Modified adeno-associated viral capsid proteins for ophthalmic gene therapy and methods of use thereof
AU2021225035A1 (en) 2020-02-21 2022-10-13 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject
MX2022012279A (en) 2020-03-31 2023-02-23 Univ Massachusetts Aav capsids variants and uses thereof.
US20230131352A1 (en) 2020-04-01 2023-04-27 Voyager Therapeutics, Inc. Redirection of tropism of aav capsids
TW202144579A (en) 2020-04-09 2021-12-01 美商４Ｍｖａｃ有限責任公司 Use of viral vectors for coronavirus vaccine production
BR112022020753A2 (en) 2020-04-15 2022-12-20 Voyager Therapeutics Inc TAU-BINDING COMPOUNDS
GB202005732D0 (en) 2020-04-20 2020-06-03 Synpromics Ltd Regulatory nucleic acid sequences
EP4165194A2 (en) 2020-05-13 2023-04-19 Akouos, Inc. Compositions and methods for treating kcnq4-associated hearing loss
CA3183171A1 (en) 2020-05-13 2021-11-18 Akouos, Inc. Compositions and methods for treating slc26a4-associated hearing loss
WO2021230987A1 (en) 2020-05-13 2021-11-18 Voyager Therapeutics, Inc. Redirection of tropism of aav capsids
WO2021247995A2 (en) 2020-06-04 2021-12-09 Voyager Therapeutics, Inc. Compositions and methods of treating neuropathic pain
KR20230038496A (en) 2020-07-13 2023-03-20 트랜스진 treatment of immunosuppression
EP4192514A1 (en) 2020-08-06 2023-06-14 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
US20240043494A1 (en) 2020-08-07 2024-02-08 Amicus Therapeutics, Inc. Vesicle Targeting Proteins And Uses Of Same
AU2021338361A1 (en) 2020-09-03 2023-04-06 Chen, Irvin S.Y Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs
GB202013940D0 (en) 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
AU2021372262A1 (en) 2020-11-02 2023-06-01 Biomarin Pharmaceutical Inc. Process for enriching adeno-associated virus
PE20240115A1 (en) 2020-12-01 2024-01-22 Akouos Inc CONSTRUCTIONS OF ANTI-VEGF ANTIBODIES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SCHWANNOMA
AU2021409952A1 (en) 2020-12-23 2023-07-06 Flagship Pioneering Innovations V, Inc. In vitro assembly of anellovirus capsids enclosing rna
EP4271419A1 (en) 2020-12-29 2023-11-08 Akouos, Inc. Compositions and methods for treating clrn1-associated hearing loss and/or vision loss
WO2022147481A1 (en) 2020-12-30 2022-07-07 Ansun Biopharma Inc. Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen
US20240141378A1 (en) 2021-03-03 2024-05-02 Voyager Therapeutics, Inc. Controlled expression of viral proteins
WO2022187473A2 (en) 2021-03-03 2022-09-09 Voyager Therapeutics, Inc. Controlled expression of viral proteins
TW202309291A (en) 2021-04-07 2023-03-01 法商新植物Ｓａｓ公司 Compositions and methods for indoor air remediation
CA3216719A1 (en) 2021-05-03 2022-11-10 Astellas Institute For Regenerative Medicine Methods of generating mature corneal endothelial cells
CA3227613A1 (en) 2021-08-11 2023-02-16 William Dowdle Inducible systems for altering gene expression in hypoimmunogenic cells
WO2023034994A1 (en) 2021-09-03 2023-03-09 Biomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
WO2023034997A1 (en) 2021-09-03 2023-03-09 Biomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
WO2023034989A1 (en) 2021-09-03 2023-03-09 Biomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
WO2023034996A1 (en) 2021-09-03 2023-03-09 Biomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
WO2023034980A1 (en) 2021-09-03 2023-03-09 Bomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
WO2023034990A1 (en) 2021-09-03 2023-03-09 Biomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2023056329A1 (en) 2021-09-30 2023-04-06 Akouos, Inc. Compositions and methods for treating kcnq4-associated hearing loss
TW202334436A (en) 2021-11-02 2023-09-01 美商航海家醫療公司 Aav capsid variants and uses thereof
WO2023091948A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
WO2023107188A1 (en) 2021-12-10 2023-06-15 Massachusetts Institute Of Technology Prediction, biosynthesis, and integration as biosensors of molecules with unique light absorbance signatures and their subsequent in-field remote detection using multi or hyper-spectral cameras
WO2023111580A1 (en) 2021-12-16 2023-06-22 University Of Dundee Targeted degradation of alpha-synuclein
WO2023147374A2 (en) 2022-01-25 2023-08-03 Voyager Therapeutics, Inc. Baculovirus expression system
WO2023150142A1 (en) 2022-02-02 2023-08-10 Akouos, Inc. Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms
TW202346599A (en) 2022-02-08 2023-12-01 美商航海家醫療公司 Aav capsid variants and uses thereof
GB202201713D0 (en) 2022-02-10 2022-03-30 Univ Dundee An affinity directed phosphatase system for targeted protein dephosphorylation
US20230365968A1 (en) 2022-04-06 2023-11-16 Genzyme Corporation Targeted gene therapy for dm-1 myotonic dystrophy
WO2023200843A1 (en) 2022-04-12 2023-10-19 The Broad Institute, Inc. Compositions and methods for screening cis regulatory elements
US20230407255A1 (en) 2022-04-12 2023-12-21 Genzyme Corporation Dendritic cell assay for innate immunogenicity to gene therapy agents
US20230405014A1 (en) 2022-04-12 2023-12-21 Genzyme Corporation Use of an irak4 modulator for gene therapy
WO2023201272A1 (en) 2022-04-12 2023-10-19 Genzyme Corporation Use of irak4 modulators for gene therapy
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023220729A2 (en) 2022-05-13 2023-11-16 Flagship Pioneering Innovations Vii, Llc Double stranded dna compositions and related methods
WO2023235791A1 (en) 2022-06-02 2023-12-07 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
WO2024006741A1 (en) 2022-06-28 2024-01-04 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
WO2024003353A1 (en) 2022-07-01 2024-01-04 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
WO2024011112A1 (en) 2022-07-06 2024-01-11 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
WO2024009280A1 (en) 2022-07-08 2024-01-11 Baylor College Of Medicine Integrated stress response inhibitors and methods of using the same
WO2024054983A1 (en) 2022-09-08 2024-03-14 Voyager Therapeutics, Inc. Controlled expression of viral proteins
WO2024059739A1 (en) 2022-09-15 2024-03-21 Voyager Therapeutics, Inc. Tau binding compounds
WO2024064856A1 (en) 2022-09-22 2024-03-28 Biomarin Pharmaceutical Inc. Treatment of cardiomyopathy with aav gene therapy vectors
WO2024064863A2 (en) 2022-09-22 2024-03-28 Biomarin Pharmaceutical Inc. Treatment of arrhythmogenic cardiomyopathy with aav gene therapy vectors
EP4345106A1 (en) 2022-09-30 2024-04-03 Charité - Universitätsmedizin Berlin Gene therapy vectors for the expression of preprodynorphin variants for the treatment of epilepsy
WO2024069010A1 (en) 2022-09-30 2024-04-04 Charité - Universitätsmedizin Berlin Gene therapy vectors for the expression of preprodynorphin variants for the treatment of epilepsy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135855A (en) * 1986-09-03 1992-08-04 The United States Of America As Represented By The Department Of Health And Human Services Rapid, versatile and simple system for expressing genes in eukaryotic cells
US5478745A (en) * 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5591601A (en) * 1993-05-14 1997-01-07 Ohio University Edison Animal Biotechnology Institute DNA polymerase gene expression system utilizing an RNA polymerase co-delivered with the gene expression vector system
EP0728214B1 (en) * 1993-11-09 2004-07-28 Medical College Of Ohio Stable cell lines capable of expressing the adeno-associated virus replication gene
DE69433592T2 (en) * 1993-11-09 2005-02-10 Targeted Genetics Corp., Seattle THE ACHIEVEMENT OF HIGH TITERS OF THE RECOMBINANT AAV VECTOR
US5693531A (en) * 1993-11-24 1997-12-02 The United States Of America As Represented By The Department Of Health And Human Services Vector systems for the generation of adeno-associated virus particles
JPH10507352A (en) * 1994-10-13 1998-07-21 ドイチェス クレブスフォルシュンクスツェントルム スチフトゥング デス エッフェントリヒェン レヒツ Preparation of rep-negative AAV mutant and cells usable therefor
US5856152A (en) * 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
US5872005A (en) * 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
WO1996017947A1 (en) * 1994-12-06 1996-06-13 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant aav vectors
FR2735789B1 (en) * 1995-06-23 1997-07-25 Centre Nat Rech Scient RECOMBINANT ADENOVIRUSES, THEIR USE FOR PREPARING AVA, COMPLEMENTARY CELL LINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Also Published As

Publication number Publication date
EP0931158A1 (en) 1999-07-28
CA2264482A1 (en) 1998-03-12
AU722624B2 (en) 2000-08-10
AU4183397A (en) 1998-03-26
JP2001500015A (en) 2001-01-09
WO1998010088A1 (en) 1998-03-12

Similar Documents

Publication Publication Date Title
IL128780A0 (en) An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase
IL128736A0 (en) Methods using cre-lox for production of recombinant adeno-associated viruses
BR9506657A (en) Comparative gene transcript analysis
IL135813A (en) Method for the preparation of citalopram
NO986202D0 (en) Method of Preparation of Recombinant Adunovirus
AU6112498A (en) Method for assembly of multiple dna fragments
GB2315252B (en) Traveling carrier system and method of controlling the same
BR9706661A (en) Process of loading an operating system
ID26243A (en) PROCESS FOR BUTANEDIOL, BUTIROLAKTON AND TETRAHIDROFURAN PROCESS
EG21056A (en) Method for refining molten silicon
EP1058282A4 (en) Switch, click for switches, and method of fixing click for switches
BR9706239A (en) Process for the preparation of 3- (1-hydroxyphenyl-1-alkoxyimino-methyl) dioxazins
HK1017380A1 (en) Method of purifying thrombin-like protease enzymesobtained from snake venom.
AU2502899A (en) Method for the elimination of pathogens from solutions containing proteins
DE69728146D1 (en) METHOD AND SYSTEM FOR CONTROLLED OVERHEAD SWITCHING
GB9813935D0 (en) Sighting system and method for temperature maeasuring
GB9814315D0 (en) Inducible promoters
ZA9710864B (en) Process for the purification of an aminoalcohol.
DE69836971D1 (en) METHOD AND APPARATUS FOR PREDICTING FUNCTIONAL PROTEINDOMAINS, METHOD FOR IMPROVING THE PROTEIN FUNCTION, AND FUNCTIONALLY IMPROVED PROTEIN
GB9827156D0 (en) Method of providing quick steering changes
AU6442998A (en) Method for the purification of virus
IL135046A0 (en) Method for purifying phthalides
AU6302698A (en) Process for the purification of substituted p-nitrodiphenylethers
ZA98943B (en) Method of purifying 1,3,5-triisopropylbenzene
AU3338597A (en) Method of purifying epsilon-caprolactam